tiprankstipranks
Oruka Therapeutics, Inc. (DE:HQ1)
NASDAQ:HQ1
Germany Market

Oruka Therapeutics (HQ1) Technical Analysis

0 Followers

Summary of all the Indicators

Overall Consensus
Strong Buy
16Bullish
5Neutral
1Bearish
Technical Analysis Consensus
Buy
5Bullish
5Neutral
0Bearish
Moving Average Consensus
Strong Buy
11Bullish
0Neutral
1Bearish
Oruka Therapeutics, Inc.’s (HQ1) Moving Averages Convergence Divergence (MACD) indicator is 4.80, suggesting Oruka Therapeutics, Inc. is a Buy.
Oruka Therapeutics, Inc.’s (HQ1) 20-Day exponential moving average is 71.32, while Oruka Therapeutics, Inc.’s (HQ1) share price is €56, making it a Buy.
Oruka Therapeutics, Inc.’s (HQ1) 50-Day exponential moving average is 62.88, while Oruka Therapeutics, Inc.’s (HQ1) share price is €56, making it a Buy.

Oruka Therapeutics (HQ1) Pivot Points

Jul 14, 2026, 05:59 PM
Name
S3
S2
S1
Pivot Points
R1
R2
R3
Classic
73.50
73.50
73.50
73.50
73.50
73.50
73.50
Fibonacci
73.50
73.50
73.50
73.50
73.50
73.50
73.50
Pivot points are a technical analysis tool used by traders to identify potential support and resistance levels in financial markets. Pivot points are calculated based on the previous day's high, low, and close prices, and are used to help traders identify levels at which the price may reverse or continue to trend.

Oruka Therapeutics (HQ1) Moving Averages

Jul 14, 2026, 05:59 PM
Period
Simple
Exponential
MA5
74.90Buy
75.21Buy
MA10
76.60Sell
74.65Buy
MA20
71.75Buy
71.32Buy
MA50
60.67Buy
62.88Buy
MA100
50.68Buy
53.36Buy
MA200
37.43Buy
40.06Buy
Oruka Therapeutics, Inc.’s (HQ1) 10-Day exponential moving average is 74.65, while Oruka Therapeutics, Inc.’s (HQ1) share price is €56, making it a Buy.
Oruka Therapeutics, Inc.’s (HQ1) 100-Day exponential moving average is 53.36, while Oruka Therapeutics, Inc.’s (HQ1) share price is €56, making it a Buy.
Oruka Therapeutics, Inc.’s (HQ1) stock price is €56 and Oruka Therapeutics, Inc.’s (HQ1) 50-day simple moving average is 60.67, creating a Buy signal.
Oruka Therapeutics, Inc.’s (HQ1) stock price is €56 and Oruka Therapeutics, Inc.’s (HQ1) 100-day simple moving average is 50.68, creating a Buy signal.
Oruka Therapeutics, Inc.’s (HQ1) stock price is €56 and Oruka Therapeutics, Inc.’s (HQ1) 200-day simple moving average is 37.43, creating a Buy signal.

Oruka Therapeutics (HQ1) Technical Indicators

Jul 14, 2026, 05:59 PM
Name
Value
Implied Action
RSI (14)
63.00
Neutral
STOCH (9,6)
10.53
Buy
STOCHRSI (14)
46.30
Neutral
MACD (12,26)
4.80
Buy
ADX (14)
35.55
Neutral
Williams %R
-68.42
Buy
CCI (14)
50.29
Neutral
ATR (14)
2.36
-
Ultimate Oscillator
47.35
Neutral
ROC
22.40
Buy
Oruka Therapeutics, Inc.’s (HQ1) Relative Strength Index (RSI) is 63.00, creating a Neutral signal.
Oruka Therapeutics, Inc.’s (HQ1) Trend Strength Indicator (ADX) is 35.55, creating a Neutral signal.
Oruka Therapeutics, Inc.’s (HQ1) Commodity Channel Index (CCI) is 50.29, creating a Neutral signal.
Oruka Therapeutics, Inc.’s (HQ1) Price Rate of Change (ROC) is 22.40, creating a Buy signal.

FAQ

Is HQ1 a Buy, Hold, or Sell?
Based on HQ1’s technical indicators, HQ1 is a Strong Buy.
    What is HQ1’s RSI (14)?
    HQ1’s RSI (14) is 63.00, which suggests HQ1 is a Neutral.
      What is HQ1’s MACD?
      HQ1’s MACD is 4.80, which suggests HQ1 is a Buy.
        What is HQ1’s 5-day moving average?
        HQ1’s 5-day moving average is 74.90, which suggests HQ1 is a Buy.
          What is HQ1’s 20-day moving average?
          HQ1 20-day moving average is 71.75, which suggests HQ1 is a Buy.
            What is HQ1’s 50-day moving average?
            HQ1’s 50-day moving average is 60.67, which suggests HQ1 is a Buy.
              What is HQ1’s 200-day moving average?
              HQ1’s 200-day moving average is 37.43, which suggests HQ1 is a Buy.
                What is HQ1’s Williams % R (14)?
                HQ1’s Williams % R (14) is -68.42, which suggests HQ1 is a Buy.
                  What is HQ1’s CCI (14)?
                  HQ1’s CCI (14) is 50.29, which suggests HQ1 is a Neutral.
                    What is the share price of Oruka Therapeutics, Inc.?